Cognition Therapeutics (NASDAQ:CGTX) and the Alzheimer’s Clinical Trials Consortium initiated the first clinical site in the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimer’s disease (AD).
The University of Kentucky Sanders-Brown Center on Aging is the first of approximately 50 sites in North America that has been activated by the consortium.
The consortium, founded in 2018 with funding from the National Institute on Aging (NIA), part of the NIH, is one of the NIA’s largest public-private partnerships.
“Without the support of the consortium and the NIA’s $81-million grant, we would likely not be in a position to offer these research participants the opportunity to test an oral once-daily medication that may slow the progression of Alzheimer’s disease,” Lisa Ricciardi, president and CEO of Cognition, said in a statement.
An estimated 540 adults with early AD who have elevated beta amyloid will be randomized to receive once-daily oral CT1812 or placebo for 18 months. CT1812 is an investigational oral, small molecule designed to bind to a receptor on synapses and prevent the toxic effects of soluble beta amyloid oligomers on neurons.
